A multinational investigation of time and traveling costs in attending anticoagulation clinics

Value in Health

Volumn 11, Issue 2, 2008, Pages 207-212

  Jowett, Sue ^a,f   Bryan, Stirling ^a   Mahé, Isabelle ^b   Brieger, David ^c   Carlsson, Jonas ^d   Kartman, Bernt ^d   Nevinson, Mark ^e  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b HÔPITAL LARIBOISIÈRE   (France)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d ASTRAZENECA R AND D   (Sweden)

^e ASTRAZENECA   (United Kingdom)

^f Health Services Management Centre   (United Kingdom)

Author keywords

Anticoagulants; Atrial fibrillation; Cost analysis; Warfarin

Indexed keywords

WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; PATIENT TRANSPORT; PRIORITY JOURNAL; QUESTIONNAIRE; TIME; TRAVEL;

EID: 41549155998     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00253.x     Document Type: Article

References (11)

1. Lowe GD. Anti-thrombotic treatment and atrial fibrillation. Editorial. BMJ 1992 305 : 1445 6.
2. Sweeney KG, Pereira-Gray D, Steele R, Evans P. Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice. Br J Gen Pract 1995 45 : 153 8.
3. Gustafsson C, Asplund K, Britton M, et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992 305 : 1457 60.
4. Blann AD. Fitzmaurice DA, Lip GYH. ABC of antithrombotic therapy: anticoagulation in hospitals and general practice. BMJ 2003 326 : 153 6.
5. Sculpher M, Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics 2000 17 : 361 70.
6. Frew E, Wolstenholme JL, Atkin W, Whynes DK. Estimating time and travel costs incurred in clinic-based screening: flexible sigmoidoscopy screening for colorectal cancer. J Med Screen 1999 6 : 119 23.
7. Bryan S, Buxton M, McKenna M, et al. Private costs associated with abdominal aortic aneurysm screening: the importance of private travel and time costs. J Med Screen 1995 2 : 62 6.
8. Parry D, Bryan S, Gee K, et al. Patient costs in anticoagulation management: a comparison of primary and secondary care. Br J Gen Pract 2001 51 : 972 6.
9. Executive Steering Committee on behalf of the SPORTIF III. Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003 362 : 1691 8.
10. Johannesson M, Borgquist L, Jönsson B. The costs of treating hypertension in Sweden. Scand J Prim Health Care 1991 9 : 155 60.
11. Barber JA, Thompson SG. Analysis of cost data in randomised trials: an application of the non-parametric bootstrap. Stat Med 2000 19 : 3219 36.